Elva Matamoros

Associate Director Program Manager - ERP | CRM | SCM | Cloud

Role: Associate Director, Project Management & Business Process Excellence at Vaxcyte
Location: San Francisco, CA, US
LinkedIn followers: 500 followers

OperationsView LinkedIn profile

About Elva Matamoros

Leader in global enterprise systems, demand to cash processes, program management, & …

Experience

Associate Director, Project Management & Business Process Excellence
Vaxcyte
Apr 2025 — Present

Education

The University of Applied Sciences HTW, Germany
Data Science

Skills

Software as a Service (Saas)
Business Intelligence
Agile Methodologies
Management
Enterprise Resource Planning (Erp)
Strategy
Oracle
Requirements Analysis
Erp Oracle
Cloud Computing
IT Strategy
Consulting
Leadership
Oracle E-Business Suite
Revenue Recognition
Quote to Cash
Soa
Enterprise Software
Enterprise Architecture
Agile Project Management
Product Management
Software Implementation
Saas
Peoplesoft
Integration
Cross-Functional Team Leadership
Cloud Applications
Project Management
Business Strategy
Start-Ups
Process Improvement
Business Process
Customer Relationship Management (Crm)
Software Project Management
Release Management
Sdlc
Solution Architecture
Strategic Planning
Business Analysis
Program Management

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
e••••••••@vaxcyte.com
Personal email
•••••@•••••.com
Direct dial
+14•••••••96

Unlock verified contacts

Free to start · No credit card required

Current company

Vaxcyte

Biotechnology Research · 580 employees · Founded 2013 · San Carlos, California, United States

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

vaxcyte.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Elva Matamoros

Experience

Associate Director, Project Management & Business Process Excellence

Education

The University of Applied Sciences HTW, Germany

Skills

Find verified contacts for anyone on LinkedIn